OSM-induced CD44 contributes to breast cancer metastatic potential through cell detachment but not epithelial-mesenchymal transition

References

• Scully OJ, Bay B-H, Yip G, Yu Y. Breast cancer metastasis. Cancer Genomics Proteomics [Internet] 2012;9:311–320. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22990110. Accessed July 5, 2019.22990110
   PubMed Web of Science ®Google Scholar
• Weigelt B, Peterse JL, van’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5:591–602. doi:10.1038/nrc167016056258
   PubMed Web of Science ®Google Scholar
• Lu X, Kang Y. Organotropism of breast cancer metastasis. J Mammary Gland Biol Neoplasia. 2007;12:153–162. doi:10.1007/s10911-007-9047-317566854
   PubMed Web of Science ®Google Scholar
• Jung SY, Rosenzweig M, Sereika SM, Linkov F, Brufsky A, Weissfeld JL. Factors associated with mortality after breast cancer metastasis. Cancer Causes Control. 2012;23:103–112. doi:10.1007/s10552-011-9859-822037907
   PubMed Web of Science ®Google Scholar
• Shapiro IM, Cheng AW, Flytzanis NC, et al. An emt-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet. 2011;7. doi:10.1371/journal.pgen.1002138
   Web of Science ®Google Scholar
• Creighton CJ, Chang JC, Rosen JM. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15:253–260. doi:10.1007/s10911-010-9173-120354771
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28:15–33. doi:10.1007/s10555-008-9169-019169796
   PubMed Web of Science ®Google Scholar
• Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–56. doi:10.1038/3506501611242036
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science (80-). 2011;331:1559–1564. doi:10.1126/science.1203543
   PubMed Web of Science ®Google Scholar
• Ma R, Feng Y, Lin S, et al. Mechanisms involved in breast cancer liver metastasis. J Transl Med. 2015;13:64. doi:10.1186/s12967-015-0541-x25885919
   PubMed Web of Science ®Google Scholar
• Tabariès S, Dong Z, Annis MG, et al. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene. 2011;30:1318–1328. doi:10.1038/onc.2010.51821076473
   PubMed Web of Science ®Google Scholar
• Tabariès S, Siegel PM. Breast cancer liver metastasis. Cancer Metastasis - Biol Treat [Internet] 2011:273–303. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L366194192%5Cndoi:10.1007/978-94-007-0292-9_10. Accessed July 5, 2019.
   Google Scholar
• Bos PD, Zhang XH-F, Nadal C, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459:1005–1009. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=19421193&retmode=ref&cmd=prlinks%5Cnpapers3://publication/doi/10.1038/nature08021. Accessed July 5, 2019.19421193
   PubMed Web of Science ®Google Scholar
• Cheng X, Hung M-C. Breast cancer brain metastases. Cancer Metastasis Rev. 2007;26:635–643. doi:10.1007/s10555-007-9083-x17717635
   PubMed Web of Science ®Google Scholar
• Zhang L, Ridgway LD, Wetzel MDA, et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med. 2013;5:180ra48. doi:10.1126/scitranslmed.3005109
   PubMed Web of Science ®Google Scholar
• Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537–549. doi:10.1016/S1535-6108(03)00132-612842083
   PubMed Web of Science ®Google Scholar
• Chen Y-C, Sosnoski DM, Mastro AM. Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res. 2010;12:215. doi:10.1186/bcr272221176175
   PubMed Web of Science ®Google Scholar
• Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived Jagged1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 2011;19:192–205. doi:10.1016/j.ccr.2010.12.02221295524
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Weaver VM, Tlsty TD, Bergers G. Tumor microenvironment and progression. J Surg Oncol. 2011;103:468–474. doi:10.1002/jso.v103.621480238
   PubMed Web of Science ®Google Scholar
• Sánchez-Tilló E, Liu Y, de Barrios O, et al. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci [Internet] 2012 [cited October 18, 2013];69:3429–3456. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22945800. Accessed July 5, 2019.22945800
   PubMed Web of Science ®Google Scholar
• Jorcyk CL, Holzer RG, Ryan RE. Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells. Cytokine. 2006;33:323–336. doi:10.1016/j.cyto.2006.03.00416713283
   PubMed Web of Science ®Google Scholar
• Ryan RE, Martin B, Mellor L, et al. Oncostatin M binds to extracellular matrix in a bioactive conformation: implications for inflammation and metastasis. Cytokine. 2015;72:71–85. doi:10.1016/j.cyto.2014.11.00725622278
   PubMed Web of Science ®Google Scholar
• Mozaffarian A, Brewer AW, Trueblood ES, et al. Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol. 2008;181:7243–7253. doi:10.4049/jimmunol.181.5.317718981146
   PubMed Web of Science ®Google Scholar
• Langdon C, Kerr C, Tong L, Richards CD. Oncostatin M regulates eotaxin expression in fibroblasts and eosinophilic inflammation in C57BL/6 mice. J Immunol. 2003;170:548–555. doi:10.4049/jimmunol.170.1.54812496442
   PubMed Web of Science ®Google Scholar
• Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res. 2005;65:8896–8904. doi:10.1158/0008-5472.CAN-04-455716204061
   PubMed Web of Science ®Google Scholar
• Pastuschek J, Poetzsch J, Morales-Prieto DM, Schleußner E, Markert UR, Georgiev G. Stimulation of the JAK/STAT pathway by LIF and OSM in the human granulosa cell line COV434. J Reprod Immunol. 2015;108:48–55. doi:10.1016/j.jri.2015.03.00225817464
   PubMed Web of Science ®Google Scholar
• Mosley B, De IC, Friend D, et al. Dual Oncostatin M (OSM) receptors. J Biol Chem. 1996;271:32635–32643. doi:10.1074/jbc.271.51.326358999038
   PubMed Web of Science ®Google Scholar
• Hutt JA, DeWille JW. Oncostatin M induces growth arrest of mammary epithelium via a CCAAT/enhancer-binding protein delta-dependent pathway. Mol Cancer Ther [Internet] 2002;1:601–610. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12479220. Accessed July 5, 2019.12479220
   PubMed Web of Science ®Google Scholar
• Grant SL, Douglas AM, Goss GA, Begley CG. Oncostatin M and leukemia inhibitory factor regulate the growth of normal human breast epithelial cells. Growth Factors. 2001;19:153–162. doi:10.3109/0897719010900108311811789
   PubMed Web of Science ®Google Scholar
• Marrero-Diaz R, Bravo-Cordero JJ, Megìas D, et al. Polarized MT1-MIVIP-CD44 interaction and CD44 cleavage during cell retraction reveal an essential role for MT1-MMP in CD44-mediated invasion. Cell Motil Cytoskeleton. 2009;66:48–61. doi:10.1002/cm.2037819023892
   PubMed Web of Science ®Google Scholar
• Stevens JW, Kurriger GL, Carter AS, Maynard JA. CD44 expression in the developing and growing rat intervertebral disc. Dev Dyn. 2000;219:381–390. doi:10.1002/(ISSN)1097-017711066094
   PubMed Web of Science ®Google Scholar
• Goebeler M, Kaufmann D, Bröcker EB, Klein CE. Migration of highly aggressive melanoma cells on hyaluronic acid is associated with functional changes, increased turnover and shedding of CD44 receptors. J Cell Sci [Internet] 1996;109(Pt 7):1957–1964. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8832418. Accessed July 5, 2019.8832418
   PubMedGoogle Scholar
• Fitzgerald KA, L A O. Characterization of CD44 induction by IL-1: a critical role for Egr-1. J Immunol [Internet] 1999;162:4920–4927. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10202038. Accessed July 5, 2019.10202038
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Takahashi K, Cutler M, Tanabe KK. O-linked glycosylation modifies CD44 adhesion to hyaluronate in colon carcinoma cells. Biochem Biophys Res Commun. 1996;227:110–117. doi:10.1006/bbrc.1996.14758858111
   PubMed Web of Science ®Google Scholar
• Lesley J, Hyman R. CD44 structure and function. Front Biosci. 1998:d616–30. doi:10.2741/A3069634544
   PubMedGoogle Scholar
• Skelton TP, Zeng C, Nocks A, Stamenkovic I. Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. J Cell Biol. 1998;140:431–446. doi:10.1083/jcb.140.2.4319442118
   PubMed Web of Science ®Google Scholar
• Wu RL, Sedlmeier G, Kyjacova L, et al. Hyaluronic acid-CD44 interactions promote BMP4/7-dependent Id1/3 expression in melanoma cells. Sci Rep. 2018;8:1–12.29311619
   PubMed Web of Science ®Google Scholar
• Zoller M, Herrlich P, Giinthert U, Herrlich P. CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res. 1991;51:5292–5297.1717145
   PubMed Web of Science ®Google Scholar
• Rodriguez C, Monges G, Rouanet P, Dutrillaux B, Lefrançois D, Theillet C. CD44 expression patterns in breast and colon tumors: a PCR-based study of splice variants. Int J Cancer. 1995;64:347–354. doi:10.1002/(ISSN)1097-02157591309
   PubMed Web of Science ®Google Scholar
• Xie J-W, Chen P-C, Zheng C-H, et al. Evaluation of the prognostic value and functional roles of CD44v6 in gastric cancer. J Cancer Res Clin Oncol. 2015;141:1809–1817. doi:10.1007/s00432-015-1964-825809905
   PubMed Web of Science ®Google Scholar
• Van Hal NLW, Van Dongen GAMS, Ten Brink CBM, et al. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma. Clin Cancer Res. 1999;5:3534–3541.10589769
   PubMed Web of Science ®Google Scholar
• Williams K, Motiani K, Giridhar PV, Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood). 2013;238:324–338. doi:10.1177/153537021348071423598979
   PubMed Web of Science ®Google Scholar
• Okamoto I, Kawano Y, Murakami D, et al. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol. 2001;155:755–762. doi:10.1083/jcb.20010815911714729
   PubMed Web of Science ®Google Scholar
• Mckallip RJ, Do Y, Fisher MT, Robertson JL, Nagarkatti PS, Nagarkatti M. Role of CD44 in activation-induced cell death: CD44-deficient mice exhibit enhanced T cell response to conventional and superantigens. Int Immunol. 2002;14:1015–1026. doi:10.1093/intimm/dxf06812202399
   PubMed Web of Science ®Google Scholar
• Iida J, Clancy R, Dorchak J, et al. DNA aptamers against exon v10 of CD44 inhibit breast cancer cell migration. PLoS One. 2014;9. doi:10.1371/journal.pone.0088712
   Web of Science ®Google Scholar
• Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241–319.9111868
   PubMed Web of Science ®Google Scholar
• Yu Q, Toole BP. A new alternatively spliced exon between v9 and v10 provides a molecular basis for synthesis of soluble CD44. J Biol Chem. 1996;271:20603–20607. doi:10.1074/jbc.271.34.206038702806
   PubMed Web of Science ®Google Scholar
• Reedeer JA, Gotley DC, Walsh MD, Fawcett J, Antalis TM. Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment. Cancer Res. 1998;58:3719–3726.9721884
   PubMed Web of Science ®Google Scholar
• Todaro M, Gaggianesi M, Catalano V, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014;14:342–356. doi:10.1016/j.stem.2014.01.00924607406
   PubMed Web of Science ®Google Scholar
• Hao J, Chen H, Madigan MC, et al. Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br J Cancer. 2010;103:1008–1018. doi:10.1038/sj.bjc.660582220736947
   PubMed Web of Science ®Google Scholar
• Hiraga T, Nakamura H. Comparable roles of CD44V8-10 and CD44S in the development of bone metastases in a mouse model. Oncol Lett. 2016;12:2962–2969. doi:10.3892/ol.2016.498527698884
   PubMed Web of Science ®Google Scholar
• Iida N, Bourguignon LY. New CD44 splice variants associated with human breast cancers. J Cell Physiol. 1995;162:127–133. doi:10.1002/jcp.10416201157529235
   PubMed Web of Science ®Google Scholar
• Mashita N, Yamada S, Nakayama G, et al. Epithelial to mesenchymal transition might be induced via CD44 isoform switching in colorectal cancer. J Surg Oncol. 2014;110:745–751. doi:10.1002/jso.2370524975268
   PubMed Web of Science ®Google Scholar
• Shang Z, Cai Q, Zhang M, et al. A switch from CD44+ cell to EMT cell drives the metastasis of prostate cancer. Oncotarget. 2015;6:1202–1216. doi:10.18632/oncotarget.284125483103
   PubMedGoogle Scholar
• Klingbeil P, Isacke CM. The “alternative” EMT switch. Breast Cancer Res. 2011;13:313. doi:10.1186/bcr305221884643
   PubMed Web of Science ®Google Scholar
• Cho SH, Park YS, Kim HJ, et al. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int J Oncol. 2012;41:211–218.22552741
   PubMed Web of Science ®Google Scholar
• Brown RL, Reinke LM, Damerow MS, et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 2011;121:1064–1074. doi:10.1172/JCI5787321393860
   PubMed Web of Science ®Google Scholar
• Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer. 2010;46:1271–1277. doi:10.1016/j.ejca.2010.02.02420303742
   PubMed Web of Science ®Google Scholar
• Valent P, Bonnet D, De Maria R, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012;12:767–775. doi:10.1038/nrc336823051844
   PubMed Web of Science ®Google Scholar
• Ricardo S, Vieira AF, Gerhard R, et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol. 2011;64:937–946. doi:10.1136/jcp.2011.09045621680574
   PubMed Web of Science ®Google Scholar
• Holzer RG, Ryan RE, Tommack M, Schlekeway E, Jorcyk CL. Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: role of cyclooxygenase-2. Clin Exp Metastasis. 2004;21:167–176. doi:10.1023/B:CLIN.0000024760.02667.db15168734
   PubMed Web of Science ®Google Scholar
• Bolin C, Tawara K, Sutherland C, et al. Oncostatin M promotes mammary tumor metastasis to bone and osteolytic bone degradation. Genes Cancer. 2012;3:117–130. doi:10.1177/194760191245828423050044
   PubMedGoogle Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25:402–408. doi:10.1006/meth.2001.126211846609
   PubMed Web of Science ®Google Scholar
• David CJ, Huang YH, Chen M, et al. TGF-?? Tumor Suppression through a Lethal EMT. Cell. 2016;164:1015–1030. doi:10.1016/j.cell.2016.01.00926898331
   PubMed Web of Science ®Google Scholar
• Pollack V, Sarközi R, Banki Z, et al. Oncostatin M-induced effects on EMT in human proximal tubular cells: differential role of ERK signaling. Am J Physiol Renal Physiol. 2007;293:F1714–26. doi:10.1152/ajprenal.00130.200717881458
   PubMed Web of Science ®Google Scholar
• Elloul S, Elstrand MB, Nesland JM, et al. Snail, slug, and smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer. 2005;103:1631–1643. doi:10.1002/cncr.2106915742334
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI. The CD44+/CD24- phenotype relates to “triple-negative” state and unfavorable prognosis in breast cancer patients. Med Oncol. 2011;28:745–752. doi:10.1007/s12032-010-9530-320405247
   PubMed Web of Science ®Google Scholar
• Mellor L, Knudson CB, Hida D, Askew EB, Knudson W. Intracellular domain fragment of CD44 alters CD44 function in chondrocytes. J Biol Chem. 2013;288:25838–25850. doi:10.1074/jbc.M113.49487223884413
   PubMed Web of Science ®Google Scholar
• Junk DJ, Bryson BL, Jackson MW. HiJAK’d signaling; the STAT3 paradox in senescence and cancer progression. Cancers (Basel). 2014;6:741–755. doi:10.3390/cancers602074124675570
   PubMed Web of Science ®Google Scholar
• Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-B and promotes tumor invasion and angiogenesis. Genes Dev. 2000;14:163–176.10652271
   PubMed Web of Science ®Google Scholar
• Ouhtit A, Madani S, Gupta I, et al. TGF-B2: A novel target of CD44-promoted breast cancer invasion. J Cancer. 2013;4:566–572. doi:10.7150/jca.663823983821
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang D, Zhang C, et al. A microRNA expression signature characterizing the properties of tumor-initiating cells for breast cancer. Oncol Lett. 2012;3:119–124. doi:10.3892/ol.2011.44422740866
   PubMed Web of Science ®Google Scholar
• Nagata T, Kai H, Shibata R, Koga M, Yoshimura A, Imaizumi T. Oncostatin M, an interleukin-6 family cytokine, upregulates matrix metalloproteinase-9 through the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cultured smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23:588–593. doi:10.1161/01.ATV.0000071350.78872.C412615664
   PubMed Web of Science ®Google Scholar
• Lilja A, Nordborg C, Brun A, Salford LG, Aman P. Expression of the IL-6 family cytokines in human brain tumors. Int J Oncol. 2001;19:495–499.11494026
   PubMed Web of Science ®Google Scholar
• Xu H, Tian Y, Yuan X, et al. The role of CD44 in epithelial-mesenchymal transition and cancer development. Onco Targets Ther. 2015;8:3783–3792.26719706
   PubMedGoogle Scholar
• Li J, Zhou BP. Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer. 2011;11:49. doi:10.1186/1471-2407-11-4921284870
   PubMed Web of Science ®Google Scholar
• Gao J, Zhu Y, Nilsson M, Sundfeldt K. TGF-β isoforms induce EMT independent migration of ovarian cancer cells. Cancer Cell Int. 2014;14:72. doi:10.1186/1475-2867-14-6725278811
   PubMed Web of Science ®Google Scholar